Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | CHKA | P35790 | 4/20 | 0.57 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.57 |
| ▸ | MC4R | P32245 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | NCF1 | P14598 | 1/20 | 0.55 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.55 |
| ▸ | BTK | Q06187 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.53 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.53 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2776747 | 0.87 | ALDH1A1 (0.59) | HDAC6LMNAHRH3MEN1KMT2A | |
| SCHEMBL28061494 | 0.86 | HDAC6 (0.71) | HDAC6LMNAHRH3CHKAMC4R | |
| SCHEMBL4699834 | 0.85 | SIGMAR1 (0.50) | HDAC6HRH3MEN1KMT2AMAP3K11 | |
| SCHEMBL16356429 | 0.85 | HDAC6 (0.69) | HDAC6LMNAHRH3MEN1KMT2A | |
| SCHEMBL1174 | 0.85 | HDAC6 (0.69) | HDAC6LMNAHRH3CHKAMC4R | |
| SCHEMBL12966235 | 0.85 | HDAC6 (0.69) | HDAC6LMNAHRH3CHKAMC4R | |
| SCHEMBL65179 | 0.85 | HDAC6 (0.69) | HDAC6LMNAHRH3MEN1KMT2A | |
| SCHEMBL1482327 | 0.85 | HDAC6 (0.69) | HDAC6LMNAHRH3CHKAMC4R | |
| SCHEMBL5839834 | 0.85 | HDAC6 (0.69) | HDAC6LMNAHRH3CHKAMC4R | |
| SCHEMBL2907506 | 0.84 | HDAC1 (0.65) | HDAC6HRH3MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120136781-A | ROR 1-targeted inhibitor and synthesis method and application thereof | 北京大学 | 2025-06-13 | — | — | CN | claimed |
| US-20220306588-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2022-09-29 | — | — | US | claimed |
| US-11453647-B2 | Benzimidazole derivatives as adenosine receptor antagonists | MERCK PATENT GMBH (DE) | 2022-09-27 | — | — | US | claimed |
| CN-110559299-A | composition containing pyridyl pyrimidinamine compound and application thereof | 黄泳华 | 2019-12-13 | — | — | CN | claimed |
| CN-106854198-B | A kind of preparation method of Imatinib | 湖南华腾医药有限公司 | 2019-11-05 | — | — | CN | claimed |
| CN-103980230-B | One prepares the method for 4-(4-methylpiperazine-l-methyl) benzamide | NORTHWEST UNIVERSITY (CN) | 2016-02-17 | — | — | CN | claimed |
| CN-103980230-A | Method for preparing 4-(4-methyl piperazine-1-methyl)-benzoyl amide | UNIV NORTHWESTERN | 2014-08-13 | — | — | CN | claimed |
| US-20120122857-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | claimed |
| WO-2010014022-A1 | A PROCESS FOR THE PREPARATION OF IMATINIB | TEMAPHARM SP. Z O.O. (PL) | 2010-02-04 | — | — | WO | claimed |
| US-20100029626-A1 | Cyclic sulfones useful as mitochondrial sodium-calcium exchangers | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | claimed |
| US-7579356-B2 | Thia-tetraazaacenaphthylene kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2009-08-25 | — | — | US | claimed |
| EP-1996558-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | Novartis AG (CH) | 2008-12-03 | — | — | EP | claimed |
| US-20080108611-A1 | SUBSTITUTED THIENOPYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-05-08 | — | — | US | claimed |
| US-20070265264-A1 | 5-(3-chloro-4-fluoro-phenyl)-4-oxo-4,5-dihydro-3H-1-thia-3,5,6,8-tetraaza-acenaphthylene-2-carboxylic acid (3,4-dimethoxy-phenyl)-amide | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-11-15 | — | — | US | claimed |
| WO-2007104538-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2007-09-20 | — | — | WO | claimed |
| WO-2007084815-A2 | SUBSTITUTED THIENOPYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-26 | — | — | WO | claimed |
| WO-2005065074-A2 | PROTECTION OF TISSUES AND CELLS FROM CYTOTOXIC EFFECTS OF IONIZING RADIATION BY ABL INHIBITORS | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2005-07-21 | — | — | WO | claimed |
| CN-120136781-A | ROR 1-targeted inhibitor and synthesis method and application thereof | 北京大学 | 2025-06-13 | — | — | CN | disclosed |
| WO-2004037261-A1 | USE OF N-‘5-‘4-(4-METHYLPIPERAZIOMETHYL)-BENZOYLAMIDO!-2-METHYLPHENYL!-4-(3-PYRIDYL)2-PYRIDINE-AMINE FOR THE TREATMENT OF PULMONARY HYPERTENSION | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2004-05-06 | — | — | WO | disclosed |
| EP-1392313-A1 | COMBINATION COMPRISING N- 5- 4-(4-METHYL-PIPERAZINO-METHYL)-BENZOYLAMIDO]-2-METHYLPHENYL -4-(3-PYRIDYL)-2PYRIMIDINE-AMINE AND A CHEMOTHERAPEUTIC AGENT | Novartis AG (CH) | 2004-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029626-A1 | Cyclic sulfones useful as mitochondrial sodium-calcium exchangers | SLC8B1, MCU, GLS | HDAC6 2385/4885LMNA 2752/4885HRH3 4557/4885 |
| US-20220306588-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA1, ADORA2A, ADORA3 | HDAC6 1370/4885LMNA 3142/4885HRH3 319/4885 |
| US-11453647-B2 | Benzimidazole derivatives as adenosine receptor antagonists | ADORA1, ADORA2A, ADORA3 | HDAC6 2353/4885LMNA 2856/4885HRH3 181/4885 |
| US-20070265264-A1 | 5-(3-chloro-4-fluoro-phenyl)-4-oxo-4,5-dihydro-3H-1-thia-3,5,6,8-tetraaza-acenaphthylene-2-carboxylic acid (3,4-dimethoxy-phenyl)-amide | ADK, MAP3K9, MAP4K5 | HDAC6 2295/4885LMNA 3244/4885HRH3 1681/4885 |
| US-20080108611-A1 | SUBSTITUTED THIENOPYRIMIDINE KINASE INHIBITORS | MAP4K2, MAP3K6, MAP3K2 | HDAC6 2550/4885LMNA 4421/4885HRH3 1921/4885 |
| US-20120122857-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | MAP3K20, PHKG1, PHKG2 | HDAC6 601/4885LMNA 2458/4885HRH3 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.